Impact of Ibis on Patients With Advanced COPD

COPD Clinical Trial

Official title:

Impact of Ibis, a Digital Health Solution for Patient Activation and Early Intervention, on Acute Care Utilization by Patients With Advanced COPD

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT03131622
• Other study ID #: Senscio-001
• Status: Enrolling by invitation
• Phase: N/A
• First received: December 13, 2016
• Last updated: April 24, 2017
• Start date: December 2016
• Est. completion date: January 2018

Study information

• Verified date: April 2017
• Source: Senscio Systems
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients with COPD.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 240
• Est. completion date: January 2018
• Est. primary completion date: January 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Gold Stage II with a CAT Score above 19

• Gold Stage III/IV with a CAT Score above 14

Exclusion Criteria:

• Cognitive or physical impediments that inhibits patients from interacting with our digital therapeutics platform.

Related Conditions & MeSH terms

• COPD

Intervention

Behavioral:
• Digital Therapeutics

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Senscio Systems	Central Maine Medical Family

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Reduction in Acute Care Utilization		6 months and then again at 1 year